Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05370885 · ClinicalTrials.gov registry record · Phase 2
VE202 in Patients With Mild-to-Moderate Ulcerative Colitis
A Phase 2 study, sponsored by Vedanta Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT05370885: Clinical Trial Phase 2 study, sponsored by Vedanta Biosciences.
NCT05370885 is a Phase 2 study that was terminated before completion, run by Vedanta Biosciences. The registered enrollment target is 114 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05370885, a Phase 2 study, was terminated before completion, sponsored by Vedanta Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).
Primary Outcome
Endoscopic response is defined as a reduction from baseline of 1 point or more in Mayo endoscopic subscore. The Mayo endoscopic subscore is evaluated on a scale of 0 to 3, with a higher score representing more severe disease.
Interventions
- DRUG Vancomycin Oral Capsule
- BIOLOGICAL VE202
- OTHER VE202 Placebo
- OTHER Vancomycin Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2023-05-08 |
| Est. Completion | 2025-08-29 |
| Phase | Phase 2 |
Why NCT05370885 stopped before completion
NCT05370885 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower).
The record links to 0 conditions, and to 4 interventions - of which Vancomycin Oral Capsule is the first listed.
NCT05370885 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05370885 about?
NCT05370885 is a clinical study titled "VE202 in Patients With Mild-to-Moderate Ulcerative Colitis". A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).
What is the current status of trial NCT05370885?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2023-05-08. Estimated completion is 2025-08-29.
What interventions are being tested in trial NCT05370885?
The interventions under investigation include: Vancomycin Oral Capsule (DRUG), VE202 (BIOLOGICAL), VE202 Placebo (OTHER), Vancomycin Placebo (OTHER).
Who is sponsoring clinical trial NCT05370885?
This trial is sponsored by Vedanta Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05370885's enrollment target sits among peer trials
114 627th of 2000 higher than 1,370 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI